Linagliptin - Boehringer Ingelheim/Eli Lilly

Drug Profile

Linagliptin - Boehringer Ingelheim/Eli Lilly

Alternative Names: BI 1356; BI 1356 BS; Dipeptidyl peptidase IV inhibitor - Boehringer Ingelheim; Ondero; Tradjenta; Trajenta; Trayenta; Trazenta

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies

Most Recent Events

  • 19 Jul 2018 Efficacy and Adverse events data from a phase IV trial in Type-2 diabetes mellitus released by Boehringer Ingelheim and Eli Lilly
  • 20 Mar 2018 Phase-III clinical trials in Type-2 diabetes mellitus (In adolescents, In children) in Portugal, USA (PO) (NCT03429543) (EudraCT2016-000669-21)
  • 12 Feb 2018 Boehringer Ingelheim plans the (DINAMO)TM phase III trial for Type II diabetes mellitus in February 2018 , (NCT03429543)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top